| A NEW
BEGINNING FOR STATIN THERAPY |
| Chairpersons: |
J. Chapman, France
J. Shepherd, Scotland |
INTRODUCTION
J. Chapman, France |
MANAGING THE HIGH-RISK PATIENT - THERAPEUTIC
APPROACHES IN 2002
H. Schuster, Germany
Discussion |
SURROGATE MARKERS OF ATHEROSCLEROSIS: IMPACT
OF STATINS
J. Kastelein, The Netherlands
Discussion |
STATIN INHIBITION OF HMG-COA REDUCTASE: A 3-DIMENSIONAL
VIEW
E. Istvan, USA |
STATINS: DIFFERENCES AND BENEFITS
F. McTaggart, UK
Discussion |
HDL-C IN ATHEROSCLEROSIS; ACTOR OR BYSTANDER?
E. Schaefer, USA
Discussion |
| Close |
Timetable